ERA Registry Figure of the month The prevalence of kidney replacement therapy in Europe and the United States Open Access

Source: Stel et al. NDT 2024: https://doi.org/10.1093/ndt/gfae040, Fig. 2b

Remarks: Figure was slightly adapted from original Figure (adding category ‘all’).

Explanation: The prevalence of kidney replacement therapy per million population (pmp) on 31 December 2021 was twice as high in the US.(2436 pmp) as in Europe (1188 pmp). Within Europe, almost half of all prevalent patients were living with a functioning graft (47%), while in the US this was only one third (32%).

Open in new tabDownload slide

ACKNOWLEDGEMENTS

The ERA Registry would like to thank the patients and staff of all the dialysis and transplant units who have contributed data via their national and regional renal registries.

CONFLICT OF INTEREST STATEMENT

A.O. received support for medical writing from Astellas and Open Health Group; grants from Sanofi; consultancy or speaker fees or travel support from Advicciene, Astellas, Astrazeneca, Amicus, Amgen, Fresenius Medical Care, GSK, Bayer, Sanofi-Genzyme, Menarini, Kyowa Kirin, Alexion, Idorsia, Chiesi, Otsuka, Novo-Nordisk and Vifor Fresenius Medical Care Renal Pharma; and is Director of the Catedra Mundipharma-UAM of diabetic kidney disease and the Catedra Astrazeneca-UAM of chronic kidney disease and electrolytes. V.S.S. received research funding grants from the European Renal Association. A.K. has no conflicts of interest to disclose.